Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016

 

 Permissions and Reprints

Abstract

Background and study aims Pancreatic cancer (PC) is the fourth most common cause of cancer death in the United States. Previous studies have suggested a survival benefit for endoscopic ultrasound (EUS), an important tool for diagnosis and staging of PC. This study aims to describe EUS use over time and identify factors associated with EUS use and its impact on survival.

Patients and methods This was a retrospective review of the Surveillance, Epidemiology and End Results (SEER) database linked with Medicare claims. EUS use, clinical and demographic characteristics were evaluated. Chi-squared analysis, Cochran-Armitage test for trend, and logistic regression were used to identify associations between sociodemographic and clinical factors and EUS. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis.

Results EUS use rose during the time period, from 7.4 % of patients in 2000 to 32.4 % in 2015. Patient diversity increased, with a rising share of older, non-White patients with higher Charlson comorbidity scores. Both clinical (receipt of other therapies, PC stage) and nonclinical factors (region of country, year of diagnosis) were associated with receipt of EUS. While EUS was associated with a survival improvement early in the study period, this effect did not persist for PC patients diagnosed in 2012 to 2015 (median survival 3 month ± standard deviation [SD] 9.8 months without vs. 4 months ± SD 8 months with EUS).

Conclusions Our data support previous studies, which suggest a survival benefit for EUS when it was infrequently used, but finds that benefit was attenuated as EUS became more widely available.

Publication History

Received: 11 May 2021

Accepted: 10 August 2021

Article published online:
14 January 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Can J Clin 2020; 70: 7-30
  CrossrefPubMedGoogle Scholar
• 2 Eloubeidi MA. et al. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc 2016; 83: 17-28
  CrossrefPubMedGoogle Scholar
• 3 Tempero MA. et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. . J Natl Compr Canc Netw 2012; 10: 703-713
  CrossrefPubMedGoogle Scholar
• 4 Ngamruengphong S. et al. EUS and survival in patients with pancreatic cancer: a population-based study. Gastrointest Endosc 2010; 72: 78-83, 83.e1–2
  CrossrefPubMedGoogle Scholar
• 5 Rustgi SD. et al. Age, socioeconomic features, and clinical factors predict receipt of endoscopic retrograde cholangiopancreatography in pancreatic cancer. World J Gastrointest Endosc 2019; 11: 133-144
  CrossrefPubMedGoogle Scholar
• 6 Shapiro M. et al. Associations of socioeconomic variables with resection, stage, and survival in patients with early-stage pancreatic cancer. JAMA Surg 2016; 151: 338-345
  CrossrefPubMedGoogle Scholar
• 7 Zeng C. et al. Disparities by Race, Age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010. JAMA Oncol 2015; 1: 88-96
  CrossrefPubMedGoogle Scholar
• 8 Schmocker RK. et al. Utilization of preoperative endoscopic ultrasound for pancreatic adenocarcinoma. HPB 2017; 19: 465-472
  CrossrefPubMedGoogle Scholar
• 9 Adler DG. et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc 2005; 62: 1-8
  CrossrefPubMedGoogle Scholar
• 10 National Cancer Institute. Overview of the SEER Program. June 23, 2017. http://seer.cancer.gov/about/overview.html
  PubMedGoogle Scholar
• 11 Amin S. et al. Metformin Improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol 2016; 111: 1350-1357
  CrossrefPubMedGoogle Scholar
• 12 Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 2006; 44: 921-928
  CrossrefPubMedGoogle Scholar
• 13 Charlson ME. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
  CrossrefPubMedGoogle Scholar
• 14 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619
  CrossrefPubMedGoogle Scholar
• 15 Klabunde CN. et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267
  CrossrefPubMedGoogle Scholar
• 16 Ruhl JL, Hurlbut CC, Ries LAG. et al. Summary Stage 2018: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2018
  PubMedGoogle Scholar
• 17 Young JL Jr, Roffers SD, Ries LAG. et al. SEER Summary Staging Manual – 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001 NIH Pub. No. 01-4969
  PubMedGoogle Scholar
• 18 Saleh MMA. et al. Preoperative endoscopic stent placement before pancreaticoduodenectomy: A meta-analysis of the effect on morbidity and mortality. Gastrointest Endosc 2002; 56: 529-534
  CrossrefPubMedGoogle Scholar
• 19 Parmar AD. et al. Evaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancer. Cancer 2013; 119: 3861-3869
  CrossrefPubMedGoogle Scholar
• 20 de Geus SW. et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery 2017; 161: 592-601
  CrossrefPubMedGoogle Scholar
• 21 Evans DB. et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502
  CrossrefPubMedGoogle Scholar
• 22 Itchins M. et al. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. Eur J Surg Oncol 2017; 43: 1711-1717
  CrossrefPubMedGoogle Scholar
• 23 Shrestha B. et al. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Med 2017; 6: 1552-1562
  CrossrefPubMedGoogle Scholar
• 24 Zhan HX, Xu JW, Wu D. et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med 2017; 16: 1201-1219
  CrossrefPubMedGoogle Scholar
• 25 Cooper GS. et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002; 40 IV-43-8 DOI: 10.1097/01.mlr.0000020943.21850.f1.
  CrossrefPubMedGoogle Scholar
• 26 Cooper GS. et al. The utility of Medicare claims data for measuring cancer stage. Med Care 1999; 37: 706-711
  CrossrefPubMedGoogle Scholar
• 27 National Cancer Institute. Measures that are limited or not available in the data. April 30, 2021. https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html
  PubMedGoogle Scholar

• Supplementary Material